Faculty Bibliography

The baboon liver in that transplant functioned well without any apparent harm to the recipient, [Thomas E. Starzl] said at a news conference after the autopsy. At the time, Starzl attributed the man's death largely to technical errors and not to rejection problems that would argue against cross-species transplants. From human and animal research, Starzl said he has come to believe that a phenomenon involving cell migration is crucial in promoting long-term acceptance of a donor organ. The phenomenon, called chimerism, involves the movement of cells from the baboon liver to elsewhere in the recipient's body, while human cells invade the baboon liver. If the transplant fails, the second recipient may be offered another baboon liver. But the man was told in the consent form he signed that he would not be eligible to receive a human liver if the baboon liver fails

A 62-year-old man became the world's second recipient of a baboon liver at the University of Pittsburgh yesterday in a transplant that was part of an effort to overcome the species barrier and alleviate the growing shortage of organs from human donors. His chronic active hepatitis B infection would most likely infect a donated human liver, making him ineligible to receive a donated human organ at most transplant centers, including the University of Pittsburgh, which is the largest center in the country, officials said. Baboon livers are believed to be resistant to hepatitis B. The second baboon-to-human liver transplant came one day after [Thomas Starzl]'s team published a scientific report on the first such transplant, which was performed last June

Parke-Davis and FDA officials said on Jan 8, 1993 that a shipment of 300,000 bottles of nitroglycerin the week of Jan 11 should end the nationwide shortage of the heart drug

Due to manufacturing problems at Parke-Davis's pharmaceuticals plant in Puerto Rico, hundreds of thousands of angina sufferers in the US may find their supplies of nitroglycerin, a heart drug, short for coming weeks. The shortage has surfaced in many cities but seems to have left others unaffected, the problems at the plant have been corrected

The nitroglycerin pills are sold as Nitrostat by Parke-Davis, a division of Warner-Lambert Co. of Morris Plains, NJ. Nitroglycerin pills are 'an extremely important drug, because they are the fastest way to stop the crushing chest pains from angina,' said [Adolf Hutter], a cardiologist at Massachusetts General Hospital in Boston. He conceded that Warner-Lambert 'should have sent out letters sooner' about the Nitrostat problem, which he said was unrelated to safety or health concerns. He attributed the situation to problems in switching to a new manufacturing process. But he offered no explanation why the old machines could not continue to be used until the problem with the new ones was solved

U.S. and European officials also say they have received reports from U.S. embassies that [Hiroshi Nakajima] offered the single deputy's job to four people from four countries influential in the election. A U.S. diplomat who is one of Nakajima's strongest critics and who spoke on condition of anonymity said that Nakajima's reelection would establish a precedent that a rich country could buy a new term for what he called an incompetent incumbent. U.S. officials have been embarrassed, however, by the support that Nakajima has received from the American Medical Association, the largest group of doctors in this country. James Todd, the AMA's executive vice president, wrote [Louis Sullivan] in July, praising Nakajima's leadership

A message from the Uruguayan government to Japanese officials in Geneva said that Uruguay would support [Hiroshi Nakajima]'s re-election with the understanding that he will appoint a Bolivian as deputy director general. Nakajima denied making such pledges. He said it was not he, but Dr. Mohammed Abdelmoumene, the organization's current deputy director who is the main opposition candidate to Nakajima's re-election, who has promised the deputy's position to others. Abdelmoumene, who denied the assertion, served as deputy director until August, when Nakajima dismissed him because he had become a rival for his job. Abdelmoumene has the support of Washington and the European Community to succeed Nakajima

The US and its European allies are mounting a campaign to oust Japan's Hiroshi Nakajima as head of the WHO, charging that his leadership in the battle against AIDS and other threats to global public health has not borne fruit

Former senator and presidential candidate Paul Tsongas was admitted to a coronary care unit on Dec 18, 1992 for monitoring of a rapid heart rhythm as a precautionary measure. Tsongas has not suffered a heart attack or heart damage

Scientists said on Dec 17, 1992 that a new vaccine developed from a genetically-altered virus has completely protected monkeys against an AIDS-like disease and hailed the finding as 'a significant advance' in the search for a human vaccine to protect against HIV